Stem Cells: Cellular and Drug Therapies. Volume 2

$179.00

Philippe Taupin, PhD
Dublin City University, School of Biotechnology, Dublin, Ireland

Series: Stem Cells – Laboratory and Clinical Research
BISAC: SCI017000

Stem cells are the building blocks of the body. They can develop into any of the cells that make up our bodies. Stem cells carry a lot of hope for the treatment of a broad range of diseases and injuries, spanning from cancers, diabetes, genetic diseases, graft-versus-host disease, eye, heart and liver diseases, inflammatory and autoimmune disorders, to neurological diseases and injuries, particularly neurodegenerative diseases, like Alzheimer’s and Parkinson’s diseases, cerebral strokes, and traumatic brain and spinal cord injuries. Stem cell research is therefore as important for our understanding the physio- and pathology of the body, as for development and therapy, including for the nervous system.

This book aims at providing an overview and in depth analysis of recent developments in stem cell research and therapy. It is composed of recently published review articles that went through a peer-review process. (Imprint: Nova Biomedical )

 

Clear

Details

Table of Contents

Introduction

Chapter 1. Adult Neurogenesis in Etiology and Pathogenesis of Alzheimer’s Disease

Chapter 2. Adult Neurogenesis and Aneuploidy in Etiology, Pathogenesis and Pathology of Alzheimer’s Disease

Chapter 3. Adult Neurogenesis, Neural Stem Cells and Alzheimer’s Disease: Developments, Limitations, Problems and Promises

Chapter 4. Oxidative Stress in Adult Neurogenesis and in the Pathogenesis of Alzheimer’s Disease

Chapter 5. Adult Neurogenesis, Neuroinflamation, and Therapeutic Potential of Adult Neural Stem Cells

Chapter 6. Adult Neurogenesis and Drug Therapy

Chapter 7. Neurogenesis and the Effect of Antidepressants

Chapter 8. Neurogenic Drugs and Compounds to Treat CNS Diseases and Disorders

Chapter 9. Patent Evaluation. Thirteen Compounds Promoting Oligodendrocyte Progenitor Cell Differentiation and Remyelination for Treating Multiple Sclerosis: Wo2010054307

Chapter 10. Patent Evaluation. Antibodies against CD20 (Rituximab) for Treating Multiple Sclerosis: US20100233121

Chapter 11. Umbilical Cord Blood and Alpha-3 Fucosyl Transferase-Treated Haematopoietic Stem Cells for Transplantation

Chapter 12. Patent Evaluation. Cell Lines Expressing Mutant FX Proteins to Generate Proteins with Reduced Rate of Fucosylation: Wo2010/141478

Chapter 13. Patent Evaluation. Modulation of GDP-Fucose Level for Generating Proteins with Reduced Rate of Fucosylation (Wo2010141855)

Chapter 14. Patent Evaluation. Chimeric Proteins Comprising the Constant Region of Immunoglobulins for Treating Haemophilia B (WO2005001025)

Chapter 15. Patent Evaluation Parthenogenetically Activated Human Oocytes and Parthenogenetic Embryonic Stem Cells: US20100233143

Chapter 16. Tuberous Sclerosis Complex: A Paradigm for Studying Adult Neurogenesis and Brain Tumors

Chapter 17. Adult Neurogenesis in Alzheimer’s Disease and Therapies

Chapter 18. Indacaterol for the Treatment of Patients with Moderate-to-Severe COPD

Conclusions

Index


 

Additional information

Binding

,